Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01585181 · ClinicalTrials.gov registry record · Phase 1
Safety and Immunogenicity of the Live Oral Cholera Vaccine Candidate PXVX0200
A Phase 1 study, sponsored by Bavarian Nordic.
- Completed
- Registry status
- Phase 1
- Development phase
- 66
- Enrollment target
NCT01585181 is a Phase 1 study that has completed, run by Bavarian Nordic. The registered enrollment target is 66 participants.
The verdict
NCT01585181, a Phase 1 study, has completed, sponsored by Bavarian Nordic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 66 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the safety and immunogenicity of a single dose of the PXVX0200 live cholera vaccine versus placebo in volunteers (Vaccinees) and whether PXVX0200, which is a live attenuated bacteria, can be transmitted to other adults living in the same household.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL PXVX0200
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2012-04 |
| Est. Completion | 2013-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01585181
The ClinicalTrials.gov registry entry for NCT01585181 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bavarian Nordic, which has 41 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01585181 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01585181 about?
NCT01585181 is a clinical study titled "Safety and Immunogenicity of the Live Oral Cholera Vaccine Candidate PXVX0200". The purpose of this study is to compare the safety and immunogenicity of a single dose of the PXVX0200 live cholera vaccine versus placebo in volunteers (Vaccinees) and whether PXVX0200, which is a live attenuated bacteria, can be transmitted to other adults living in the same household.
What is the current status of trial NCT01585181?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 66 participants. The study started on 2012-04. Estimated completion is 2013-01.
What interventions are being tested in trial NCT01585181?
The interventions under investigation include: Placebo (BIOLOGICAL), PXVX0200 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01585181?
This trial is sponsored by Bavarian Nordic, which has 41 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.